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Abstract
Introduction: Non-tuberculous mycobacterial lung diseases (NTMLD) occur rarely and are diagnosed mainly in patients belonging 
to risk groups. Pulmonary hypertension (PH) has not been recognised as a risk factor for NTMLD yet.
The aim of the study was to analyse the clinical course and predisposing factors of NTMLD recognised in our centre between 
2002 and 2012 in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial 
hypertension (IPAH). 
Material and methods: Thirteen patients (10 — CTEPH, 3 — IPAH) entered the study. PH was recognised during right heart 
catheterisation. Median value of mean pulmonary artery pressure (mPAP) was 49 mm Hg (39–65 mm Hg). NTMLD was diagnosed 
according to ATS guidelines (2007).
Results: M. kansasii was the most frequent pathogen. Most patients complained of the exaggeration of dyspnoea and productive 
cough. Computed tomography of the chest with angiography revealed infiltrations with cavitation in seven patients and cavities 
surrounded by micronodules in six patients. In all CTEPH patients, NTMLD developed in the hypoperfused lung areas. No paren-
chymal abnormalities preceded the development of NTMLD. After diagnosis all of the patients received antituberculous treatment; 
in 12/13 improvement was achieved. By the end of March 2014 seven patients died due to right heart insufficiency, no deaths 
due to NTMLD were noted. 
Conclusions: NTMLD should be suspected in patients with CTEPH or IPAH, presenting with productive cough and a new pulmo-
nary infiltrate with cavitation. In patients with CTEPH, special attention should be paid to a new cavitary lesions without accompa-
nying thrombus in the artery supplying the area. High mPAP (CTEPH/IPAH) and hypoperfusion (CTEPH) are predisposing to NTMLD. 
Key words: non-tuberculous mycobacterial lung disease, chronic thromboembolic pulmonary hypertension, idiopathic pulmonary 
arterial hypertension, lung hypoperfusion
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Streszczenie
Wstęp: Mikobakteriozy są chorobami rzadkimi, rozpoznawanymi głównie u osób z grup ryzyka. Wśród płucnych czynników ryzyka 
nie wymieniono dotychczas nadciśnienia płucnego. 
Celem pracy była analiza obrazu klinicznego i przebiegu mikobakteriozy płuc, którą rozpoznano w ośrodku autorów pracy w latach 
2002–2012 u chorych na nadciśnienie płucne zakrzepowo-zatorowe (CTEPH) i idiopatyczne (IPAH), oraz próba określenia czynni-
ków sprzyjających zachorowaniu. 
Materiał i metody: Badaną grupę stanowiło 13 chorych — 10 z CTEPH i 3 z IPAH. Nadciśnienie płucne potwierdzono metodą inwa-
zyjną. Mediana średniego ciśnienia w tętnicy płucnej w okresie rozpoznania mikobakteriozy wynosiła 49 mm Hg (39–65 mm Hg). 
Mikobakteriozę płuc rozpoznano zgodnie z kryteriami Amerykańskiego Towarzystwa Chorób Płuc z 2007 roku. 
Wyniki: Czynnikiem etiologicznym był u większości chorych gatunek M. kansasii. Najczęstszymi objawami mikobakteriozy płuc 
były nasilenie duszności i produktywny kaszel. W tomografii komputerowej klatki piersiowej z opcją naczyniową w 7 przypadkach 
stwierdzono zagęszczenia miąższowe z rozpadem, w 6 — jamy otoczone drobnymi guzkami. U wszystkich chorych na CTEPH 
zmiany związane z mikobakteriozą pojawiły się na obszarach o upośledzonej perfuzji, ale bez widocznych zmian pozawałowych. 
Wszyscy chorzy otrzymali leczenie przeciwprątkowe, uzyskano poprawę w 12/13 przypadków. Do kwietnia 2014 roku 7 chorych 
zmarło z powodu ciężkiej prawokomorowej niewydolności serca, nie obserwowano zgonów w przebiegu mikobakteriozy.
Wnioski: Nowe płucne zmiany miąższowe z rozpadem u chorych na CTEPH i na IPAH z towarzyszącym produktywnym kaszlem 
powinny skłonić do diagnostyki w kierunku mikobakteriozy płuc. W CTEPH niepokój budzą szczególnie ogniska rozpadu, którym 
nie towarzyszą nowe skrzepliny w naczyniach doprowadzających. Czynnikami sprzyjającymi rozwojowi mikobakteriozy płuc są: 
wysokie nadciśnienie płucne (CTEPH i IPAH) oraz obniżona perfuzja (CTEPH). 
Słowa kluczowe: mikobakterioza płuc, nadciśnienie płucne zakrzepowo-zatorowe, idiopatyczne tętnicze nadciśnienie płucne, 
hipoperfuzja płuc
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Introduction
Non-tuberculous mycobacterial lung diseases 
(NTMLD) are caused by non-tuberculous myco-
bacteria, also known as atypical mycobacteria. 
They are saprophytic bacteria, which are widely 
spread in the environment, among others in soil 
and in water [1, 2]. Infection with atypic myco-
bacteria happens due to inhalation of pathogens 
included in water aerosols, soil derived dust, 
or through injured skin. Atypical mycobacteria 
cause mainly lung disease; they rarely cause 
lymphadenitis, dermatitis, soft tissue infection, 
or disseminated disease [1, 2]. 
NTMLD occur rarely. According to data 
published in 2007 by the ATS, the estimated 
incidence rate of NTMLD in developed coun-
tries varied from 1.0 to 1.8 cases per 100,000 [1]. 
Research conducted in several states in the USA 
between 2004–2006 showed a higher incidence 
rate — 5.4 per 100,000 [3]. Similar observations 
were made in the state of Oregon in 2005 and 
2006, where the incidence rate of NTMLD was 
estimated at 5.6 cases per 100,000 [4]. NTMLD 
occur more frequently in people living in warm 
and humid climatic zones, due to more intensive 
exposure to the environmental mycobacteria. In 
northern Australia, where the climate is hot and 
tropical, and where NTMLD is registered, in the 
years 1989–1997 the incidence rate amounted to 
3.9 per 100,000 people [5]. 
NTMLD is also more frequent in people 
whose profession is connected with the mining 
and smelting industry [1, 6, 7], and in smokers. 
Tobacco smoke and exposure to inorganic dusts 
damage the mucous membrane of the respiratory 
system, causing impairment of local mechanisms 
of defence. 
According to the literature, NTMLD is most 
often caused by M. avium complex (MAC) [8, 9], 
then by M. kansasii, M. xenopi, M. malmoense, 
and rapidly growing mycobacteria (RGM). In 
Poland, according to several available studies 
and the data of the National Institute of Hygie-
ne, NTMLD is most frequently caused by M. 
kansasii [10–12].
The disease that is caused by non-tuberculo-
us mycobacteria mainly affects people from risk 
groups. The risk groups of NTMLD include the 
following:
— individuals with past or current lung disease 
(COPD, bronchiectasis, cystic fibrosis, past 
pulmonary tuberculosis, cystic disease of the 
lungs, silicosis, allergic broncho-pulmonary 
aspergillosis, pulmonary alveolar proteino-
sis) [1, 2, 8];
— individuals with deformation of the chest 
such as kyphoscoliosis and pectus excava-
tum [13];
— patients exposed to the aspiration of gastric 
contents in the course of gastroesophageal 
reflux, achalasia of the oesophagus [6, 14];
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— patients with generalised disorders of im-
munity (neoplastic diseases, HIV infection, 
immunosuppressive treatment) [1, 6]. 
NTMLD has also been found in persons with 
rheumatologic diseases or inflammatory bowel 
diseases, treated with TNFa antagonists such as 
monoclonal antibodies — infliximab and adali-
mumab, and TNFa receptor antagonist — etaner-
cept [6, 15]. The risk of occurrence of NTMLD is 
significantly higher in individuals with genetic 
disorders concerning IFN-g or IL-12 receptors [6, 
8, 16]. Important sources of infection are factors 
connected with medical care [1, 17], in particular 
hospital water intakes, water used for ice pro-
duction or for dialysis, and long-lasting central 
catheterisation. There have been reported cases 
of hospital infections after various operations, 
particularly those concerning plastic surgery, 
cardiosurgery, or during bronchoscopy. 
The recently reported increase in the inciden-
ce of NTMLD is presumably related to improved 
laboratory diagnostics and a growing number 
of people from risk groups [18, 19]. To date, the 
relation between PH and NTMLD has not been 
described. Our group published the only study 
concerning this issue [20]. As subsequent cases of 
NTMLD in patients with PH in the following years 
have been diagnosed in our clinic, we decided to 
pay attention to this clinical problem. 
The objective of the study was to analyse 
the clinical image and the course of NTMLD in 
patients with CTEPH and IPAH, and to define 
potential risk factors of NTMLD in patients with 
pulmonary hypertension. 
Material and methods
The study group included 13 patients 
(10 with CTEPH, 3 with IPAH), who were dia-
gnosed with NTMLD between 2002 and 2012. 
Pulmonary hypertension was confirmed using 
right heart catheterisation in all patients; howe-
ver, the results for only 11 persons were availa-
ble. One female patient with CTEPH underwent 
cardiac catheterisation at another centre and at 
present we have n ot had access to the results 
of the examination. In another female patient 
after urgent, ineffective thromboendarterectomy 
of the pulmonary artery, post-operative cardiac 
catheterisation was not performed due to the poor 
health condition of the patient and no prospect 
for further causal treatment. 
Thromboembolic pulmonary hypertension 
was diagnosed based on chest spiral CT scan with 
angiography or arteriography of the pulmonary 
artery, which showed typical filling defects of 
the pulmonary artery. IPAH was diagnosed after 
exclusion of other causes of PH. NTMLD was 
diagnosed in accordance with the criteria of the 
American Thoracic Society (ATS) of 2007 [1] in 
the patients with new clinical symptoms of lung 
disease, new radiological signs that suggested 
NTMLD, and if microbiological criteria were met 
(positive sputum culture results from at least two 
separate samples or positive culture results from 
at least one bronchial washing sample).
Results
Clinical data of the patients are presented in 
Table 1. The study group included eight men and 
five women, median age was 34 years (range from 
22 to 76 years). Most of the patients had low body 
mass index, median BMI was 23 kg/m2 (17.6–27.7). 
The most frequent sign of NTMLD was 
exaggeration of dyspnoea, which was found in 
11 patients. Eight patients complained of cough 
(productive, with the expectoration of purulent 
sputum, in six; dry in two). Haemoptysis, eleva-
ted body temperature, pleuritic chest pain, and 
strength reduction were found sporadically. 
Chest angio CT scans performed prior to 
the diagnosis of NTMLD and those that were 
performed at the time of NTMLD were analysed. 
In all patients with CTEPH, the scans performed 
prior to the diagnosis revealed mosaic perfusion 
including more than 50% of the lung fields. In 
six out of ten patients angio CT scan showed po-
stinflammatory and postinfarction scars, which 
in five cases were located in areas other than 
later lesions in the course of NTMLD, and in one 
patient — in the same area. 
In all patients with IPAH, parenchymal ab-
normalities were found, in two cases they were 
ground-glass opacities, and in one case they were 
nodules of the central part of the pulmonary lo-
bule located in the whole lungs. Furthermore, in 
all patients, chest angio CT showed the features 
of significant pulmonary hypertension; median 
width of pulmonary artery trunk was 38 mm 
(the normal size is up to 29 mm). In the group of 
CTEPH patients, in five cases, proximally located 
thrombi were found, whereas in five patients 
thrombi were distal (segmental vessels). Chest 
angio CT scans performed when NTMLD was 
diagnosed revealed the following:
— in seven patients — infiltrations with cavitation 
and with the presence of small satellite nodules;
— in six persons — cavities surrounded by 
micronodules (Fig. 1). 
Pneumonologia i Alergologia Polska 2014, tom 82, nr 6, strony 495–502 
498 www.pneumonologia.viamedica.pl
Table 1.  Age, BMI, clinical and radiological symptoms, and the number of positive sputum (S) and bronchial washing 
(BW) examinations targeted at mycobacteria in individual patients (Pt) with diagnosed mycobacteriosis
Pt Diagnosis Age 
(years)
BMI 
[kg/m²]
Clinical symptoms Radiological symptoms Positive examination targeted  
at mycobacteria
Direct  
examination  
S/BW
Culture 
S 
Culture 
BW
1 CTEPH 33 23.4 Intensified dyspnoea Cavity, satellite nodules 2 2 1
2 CTEPH 47 17.6 Cough, strength reduction, 
intensified dyspnoea
Cavity, satellite nodules – 2 1
3 CTEPH 67 24.1 Intensified dyspnoea Infiltrations with cavitation, 
satellite nodules
– 1 1
4 CTEPH 49 27.7 Intensified dyspnoea Infiltrations with cavitation, 
satellite nodules
– 1 1
5 CTEPH 59 23.4 Cough, haemoptysis, inten-
sified dyspnoea
Thick-walled cavities, satel-
lite nodules
1 3 1
6 CTEPH 25 22.9 Intensified dyspnoea Infiltrations with cavitation 1 1 1
7 CTEPH 25 18.4 Cough, strength reduction, 
intensified dyspnoea
Infiltrations with cavitation, 
satellite nodules
2 2 1
8 CTEPH 33 19.6 Haemoptysis, dyspnoea, 
cough
Infiltrations with cavitation 1 2 1
9 CTEPH 34 21.1 Cough, intensified dyspno-
ea, subfebrile body tempe-
rature
Thick-walled cavities, satel-
lite nodules
4 4 –
10 CTEPH 54 31.3 Cough Infiltrations with cavitation – 1 1
11 IPAH 76 23 Fever, pain in the chest, 
intensified dyspnoea
Cavity, satellite nodules 2 3 –
12 IPAH 22 21.4 Cough, dyspnoea Cavity, satellite nodules – – 1
13 IPAH 30 23.2 Cough Infiltrations with cavitation, 
satellite nodules
– – 1
A B
Figure 1. High-resolution CT (HRCT) in the patient with CTEPH and mycobacterial lung disease, performed before and after treatment of myco-
bacteriosis. A — HRCT performed before treatment of mycobacterial lung disease: thick-walled cavity with satellite nodules localised in the right 
upper lobe, with infiltration localised in left upper lobe; B — HRCT taken after treatment: marked regression of lung infiltrations, post-inflammatory 
scars seen in both regions
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Figure 2. Chest angio CT — frontal view (reconstruction) in a patient 
with CTEPH and mycobacterial lung disease. The cavity seen in the 
right lung is localised in the hypoperfused area
Table 2.  Selected echocardiographic and haemodynamic parameters in individual patients (Pt) with mycobacteriosis 
(1–10: CTEPH patients, 11–13: IPAH patients) 
Pt TVPG 
[mm Hg]
AcT [ms] rPK 
[mm]
RAP 
[mm Hg]
PAPm 
[mm Hg]
PCWP 
[mm Hg]
CO [l/m²] SatO2mv 
(%)
CI [l/min/
m2]
PVR 
[Wood’s 
units]
SatO2 
art. (%)
1 86 67 34 13 46 4 4.23 49 2.25 9.93 90
2 46 70 33 9 39 10 4.15 65 2.17 6.99 94
3 90 53 49 13 58 8 4.14 54 2 12.08 85
4 82 53 33 21 65 8 4 49 2.21 14.25 93
5 75 40 43 9 49 8 4 61 2.18 10.25 85
6 77 50 47 7 44 6 5.3 73 3.02 7.17 94
7 103 60 34 14 65 8 4.04 47 2.09 14.11 96
8 65 78 30 6 48 4 4.95 64 2.53 8.89 98
9 80 53 44 ND ND ND ND ND ND ND ND
10 38 80 36 ND ND ND ND ND ND ND ND
11 83 73 30 9 54 11 3.43 43 2.13 12.54 89
12 91 53 50 6 54 6 3.07 38 1.68 15.64 93
13 76 63 36 21 49 9 6.03 68 3.05 6.14 94
TVPG — tricuspid valve peak gradient; Act — pulmonary artery acceleration time; rPK — right ventricular diastolic diameter; RAP — right atrial pressure; PAPm — 
mean pulmonary artery pressure; PCWP — pulmonary artery wedge pressure; CO — cardiac output; sat O2 mv — mixed venous blood oxygen saturation; CI — cardiac 
index; PVR — pulmonary vascular resistance; SatO2 art. — arterial blood oxygen saturation; ND — no data
In all patients with CTEPH, lesions related 
to NTMLD occurred in hypoperfused lung areas 
(Figure 2). In eight patients with CTEPH, there 
were no reports of new thrombi in pulmonary 
arteries at the time when NTMLD occurred, and 
in two — new thrombi of different location than 
lesions in the course of NTMLD appeared.
In 11 patients, NTMLD was caused by 
M. kansasii, and in one person — by M. xenopi. 
In one patient, M. kansasii was originally cul-
tured then, one year later, a new infection with 
M. xenopi was found. In two patients, diagnosis 
was microbiologically confirmed by a single sam-
ple of bronchial washings, in the subsequent two 
patients — by at least three sputum specimens, 
and in the remaining patients — by at least two 
cultures from sputum and from bronchial washin-
gs. Mycobacteria in the direct preparation were 
found in seven patients (Tab. 1). 
In the majority of patients, at the time of 
NTMLD, high pulmonary hypertension was pre-
sent. The results of echocardiography and right 
heart catheterisation are presented in Table 2. 
The median value of the tricuspid valve pressure 
gradient (TVPG) in echocardiography was 80 
mm Hg (38–103 mm Hg), whereas the median  of 
mean pulmonary arterial pressure (mPAP) was 
49 mm Hg (39–65 mm Hg). Those patients were 
distinguished by low values of cardiac index (CI) 
[median CI: 2.18 l/min/m² (1.68–3.05 l/min/m2)], 
cardiac output (CO) [median CO: 4.14 l/min (3.07–
6.03 l/min)], and mixed venous blood saturation 
(SatO2mv) [median SatO2mv: 54% (38–73%)]. 
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In 11/13 patients, advanced WHO class was 
found (nine persons — III, two persons — IV), the 
remaining two persons were in II class. Median 
value of N-terminal fraction of brain natriuretic 
peptide (NTproBNP) was 2195 pg/ml (723–9663 
pg/ml), which confirmed additionally the presen-
ce of advanced right heart insufficiency.
In the study group, we found no increased 
frequency of diseases of the respiratory system 
that are known risk factors of NTMLD. Only in 
one female patient with IPAH, past pulmonary 
tuberculosis was found (location of post-tuber-
culous lesions did not correspond to the location 
of lesions in the course of NTMLD), and in one 
patient with CTEPH, hiatus hernia was diagno-
sed. All patients were qualified for treatment of 
NTMLD. Most of the patients were treated with 
rifampicin (RMP), isoniazid (INH) and ethambu-
tol (EMB) (Tab. 3). Median treatment time was 
18 months (3–26 months). Positive results of tre-
atment were achieved in 12 patients: regression 
of clinical symptoms, regression of radiological 
lesions (Figure 1), and sterilisation of sputum 
specimens. In one female patient, no radiological 
improvement was observed. Seven patients (6 — 
CTEPH and 1 — IPAH) died before April 2014. 
In all cases, the cause of death was severe right 
heart insufficiency. In no case was NTMLD the 
cause of death. Median time from the diagnosis of 
NTMLD to death was 25 months (8–84 months). 
Discussion
Non-tuberculous mycobacterial lung disease 
occurs mainly in individuals from risk groups. 
According to the literature, the incidence of 
NTMLD in patients with cystic fibrosis amounts 
to approximately 3% [21], in patients with bron-
chiectasis 2–3% [22, 23], and in persons with past 
pulmonary tuberculosis approximately 2% [24]. 
Higher incidence was observed in individuals tre-
ated with anti-TNFa preparations [25] and in HIV 
infected patients, in whom the risk of infection 
increases together with lowering of lymphocyte 
count CD4+ [26]. 
The present observational study, conducted 
at the pulmonary hypertension treatment cen-
tre, showed that during ten years NTMLD was 
diagnosed in 11 patients with thromboembolic 
pulmonary hypertension and in three patients 
with idiopathic pulmonary arterial hypertension. 
In a PhD thesis of E. Wilińska, the prevalence of 
NTMLD in patients with CTEPH and IPAH in the 
years 2002–2008 was estimated at 3.5% [27].
These data show that the incidence of NTMLD 
in patients with pulmonary hypertension (CTEPH 
and IPAH) is similar to the incidence of NTMLD 
in patients with other chronic pulmonary diseases 
that are considered to be risk groups. 
In 12 cases from the study group, the path-
ogen was M. kansasii. This mycobacterium spe-
cies is the most frequent cause of NTMLD in Po-
land, which is confirmed in the literature [10, 11] 
and by the National Institute of Hygiene [12]. In 
studies conducted in other countries, the most 
frequent cause of NTMLD was MAC, whereas M. 
kansasii was the second (in terms of frequency) 
cause of NTMLD in some regions of the USA, 
Great Britain, and Japan [1]. 
In the present study, in patients with NT-
MLD and PH, the most frequent signs of NTMLD 
were exaggeration of dyspnoea and productive 
cough. Exercise dyspnoea and restricted exer-
cise tolerance are reported by the majority of 
patients with advanced pulmonary hyperten-
sion; these symptoms depend in most cases on 
the degree of heart insufficiency, and in CTEPH 
patients, they may be related to progression 
or the appearance of new thrombi in the pul-
monary vessels. In the opinion of the authors, 
diagnostics targeted at respiratory system in-
fection should be implemented in every case 
of unclear cause of worsened exercise tolerance 
in patients with PH, particularly in the indivi-
duals with productive cough. It is emphasised 
in the literature that the symptoms of NTMLD 
are untypical, and they usually include chronic 
or recurrent cough with sputum expectoration, 
rarely strength reduction, subfebrile body tem-
perature, haemoptysis, pain in the chest, weight 
loss, and dyspnoea [1, 2, 28, 29]. 
In the radiological image of patients with 
pulmonary hypertension and NTMLD, infiltra-
tions with cavitation or cavities with satellite 
nodules were found. Such a radiological image 
Table 3.  Treatment schedules applied in patients with 
mycobacteriosis and pulmonary hypertension
Number  
of patients
Treatment
7 RMP, INH, EMB
2 RMP, INH, clarithromycin
1 RMP, INH, ofloxacin
1 RMP, INH, EMB, clarithromycin
1 RMP, EMB, ofloxacin, amikacin
1 INH, EMB, ofloxacin, clarithromycin
RMP — rifampicin; INH — isoniazid; EMB — ethambutol
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is typical of the disease caused by M. kansasii 
and M. xenopi [1]. 
The appearance of new infiltrations with 
cavitation in CTEPH patients may arouse a suspi-
cion of the recurrence of pulmonary embolism. 
A significant diagnostic element in such cases 
is the presence or lack of new embolic lesions 
in the vessels supplying blood to the area of the 
lesion. The lack of new vascular lesions in CTEPH 
patients in whom new infiltrations and cavitation 
are found in chest angioCT scan, should lead to 
diagnostics targeted at the respiratory system 
infection. In the study group, in eight cases, new 
infiltrations with cavitation that were found on 
chest angio CT scan, were not accompanied by 
vascular lesions, and in two cases new thrombi 
were found, but they were located outside the 
area with infiltrations. 
Among the factors that could influence an 
increased risk of NTMLD in patients with PH, 
structural lesions that could be the base for co-
lonisation with non-tuberculous mycobacteria, 
such as scars, foci of fibrosis, or postinfarction 
cavities in CTEPH patients, were taken into con-
sideration. It was shown that only in one CTEPH 
patient, NTMLD developed in the area where po-
stinfarction scar was seen previously. In another 
five CTEPH patients, on the chest angio CT scan 
that preceded NTMLD, postinflammatory and 
postinfarction scars were found, but they were 
located in other regions of the lungs. 
Among IPAH patients, in two cases the exami-
nation that preceded NTMLD showed delicate opa-
cities located in the whole lungs, and in one case, 
nodules of the central pulmonary lobule. These 
symptoms had been described in the examinations 
performed several years prior to the development 
of NTMLD. In the opinion of authors, these abnor-
malities were not an early manifestation of NTMLD 
because in those patients, radiological changes cor-
responding to infection with M. kansasii, similarly 
to other patients from this group, took the form of 
infiltrations with cavitation. 
In IPAH patients, parenchymal lesions in the 
form of focal ground-glass opacities or nodules in 
the central part of the pulmonary lobule, which 
are seen on high-resolution CT (HRCT) scan, 
are rare. In our own research, among 48 IPAH 
patients, they were found in 25% and 17% of 
cases, respectively [30]. The presence of nodules 
correlated with more advanced pulmonary hyper-
tension and was an adverse prognostic factor [30]. 
The most interesting conclusions concerning 
CTEPH patients emerged from the analysis of 
correlation between the location of lesions in 
the course of NTMLD and the features of mosaic 
perfusion. Mosaic perfusion, found on HRCT 
scan in the patients with CTEPH, is defined as 
the occurrence of areas of better and worse per-
fusion, due to local blood flow impairment in 
the course of pulmonary arterial obliteration. In 
the study group, it was found that in all cases of 
CTEPH the foci of NTMLD were located in poorly 
perfused areas. 
During the analysis of echocardiography and 
cardiac catheterisation, attention was paid to the 
fact that NTMLD concerned patients with high 
pulmonary pressure and significant impairment 
of the function of the right heart ventricle. Median 
TVPG was 80 mm Hg, whereas median mPAP 
was 49 mm Hg. The majority of patients had 
lowered values of cardiac index, cardiac output, 
and mixed venous blood oxygen saturation. An 
additional parameter that confirmed the presen-
ce of the impairment of the right heart ventricle 
function was a high value of NTproBNP. 
Most patients (12 out of 13) responded positi-
vely to antituberculous treatment, which resulted 
in clinical and radiological improvement coupled 
with sterilisation of sputa. However, more than 
half of the patients (7 out of 13) died shortly after 
the diagnosis of non-tuberculous mycobacterial 
lung disease (the median time from the diagnosis 
of NTMLD to death was 25 months). The direct 
cause of death in all cases was right heart insuf-
ficiency in the course of advanced pulmonary 
hypertension. 
It seems that infection with non-tuberculous 
mycobacteria could have an impact on survival in 
the study group. However, it was also the group 
with advanced pulmonary hypertension, right he-
art insufficiency, and poor prognosis. The median 
concentration of NTproBNP was 2195 pg/ml and 
significantly exceeded the value of 1400 pg/ml, 
which was considered to be a negative progno-
stic factor in patients with PH by Fijalkowska et 
al. [31]. In the above-mentioned paper, 44% of 
patients who had a concentration of NTproBNP 
higher or equal to 1400 pg/ml died during three-
-year follow-up [31]. 
In the literature, there are reports concerning 
the negative impact of infection on the course of 
PH and prognosis of the patients. Infections are a 
frequent cause of exacerbations of right heart in-
sufficiency in this group of patients, particularly 
in cases of advanced pulmonary hypertension [32, 
33]. Infection with non-tuberculous mycobacteria 
causing a chronic inflammatory condition could 
undoubtedly have negatively influenced the cour-
se of pulmonary hypertension in the study group.
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